Diagnosis and treatment of polycystic ovarian syndrome in adolescents

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 6, 2012, Pages 497-504

  Nicandri, Katrina F ^a   Hoeger, Kathleen ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

adolescent; hyperandrogenism; polycystic ovarian syndrome

Indexed keywords

ADIPOCYTOKINE; ANDROSTENEDIONE; ANTIANDROGEN; ESTRADIOL; FLUTAMIDE; FOLLITROPIN; HYDROXYPROGESTERONE; INSULIN; LIPID; LUTEINIZING HORMONE; METFORMIN; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PROLACTIN; SPIRONOLACTONE; TESTOSTERONE; THYROTROPIN;

ACNE; ADIPOCYTE; ADOLESCENCE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET THERAPY; EVIDENCE BASED MEDICINE; EXERCISE; HERITABILITY; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LARGE FOR GESTATIONAL AGE; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW BIRTH WEIGHT; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRECOCIOUS PUBERTY; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT INDICATION; VIRILIZATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; BODY IMAGE; CONTRACEPTIVES, ORAL, HORMONAL; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; MENSTRUATION DISTURBANCES; OBESITY; POLYCYSTIC OVARY SYNDROME; QUALITY OF LIFE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84869866575     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835a1a03     Document Type: Review

References (90)

1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181-191.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078-3082.
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223-1236.
4. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002; 16:263-272.
5. Bronstein J, Tawdekar S, Liu Y, et al. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol 2011; 24:15-20.
6. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. . Boston: Blackwell Scientific Publications; 1992; 377-384.
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
8. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456-488.
9. Zachurzok-Buczynska A, Szydlowski L, Gawlik A, et al. Blood pressure regulation and resting heart rate abnormalities in adolescent girls with polycystic ovary syndrome. Fertil Steril 2011; 96:1519-1525.
10. Legro RS, Lin HM, Demers LM, Lloyd T. Rapid maturation of the reproductive axis during perimenarche independent of body composition. J Clin Endocrinol Metab 2000; 85:1021-1025.
11. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006; 60:759-763.
12. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787-796.
13. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006; 91:786-789.
14. Hickey M, Doherty DA, Atkinson H, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011; 26:1469-1477.
15. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab 2006; 91:3786-3790.
16. van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril 2000; 74:49-58.
17. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:28e25-38e25.
18. van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 2004; 19:383-392.
19. Fruzzetti F, Perini D, Lazzarini V, et al. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 2009; 92:626-634.
20. Waldstreicher J, Santoro NF, Hall JE, et al. Hyperfunction of the hypothalamicpituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66:165-172.
21. Haisenleder DJ, Dalkin AC, Ortolano GA, et al. A pulsatile gonadotropinreleasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology 1991; 128:509-517.
22. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2248-2256.
23. Miller WL. Steroidogenic enzymes. Endocr Dev 2008; 13:1-18.
24. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010; 122:42-52.
25. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141-146.
26. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165-169.
27. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83:2001-2005.
28. Qin KN, Rosenfield RL. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol 1998; 145:111-121.
29. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of folliclestimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996; 81:302-309.
30. Tosi F, Negri C, Perrone F, et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2012; 97:1712-1719.
31. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diabetes Rep 2011; 11:179-184.
32. Iuorno MJ, Islam LZ, Veldhuis PP, et al. Leptin secretory burst mass correlates with body mass index and insulin in normal women but not in women with polycystic ovary syndrome. Metabolism 2007; 56:1561-1565.
33. Plati E, Kouskouni E, Malamitsi-Puchner A, et al. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril 2010; 94:1451-1456.
34. Yildizhan R, Ilhan GA, Yildizhan B, et al. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. Fertil Steril 2011; 96:246-250.
35. O'Connor A, Phelan N, Tun TK, et al. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab 2010; 95:1378-1385.
36. Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, Skalba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 154:51-56.
37. Psilopanagioti A, Papadaki H, Kranioti EF, et al. Expression of adiponectin and adiponectin receptors in human pituitary gland and brain. Neuroendocrinology 2009; 89:38-47.
38. Olszanecka-Glinianowicz M, Madej P, Zdun D, et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2012; 162:55-61.
39. Sopher AB, Gerken AT, Blaner WS, et al. Metabolic manifestations of polycystic ovary syndrome in nonobese adolescents: retinol-binding protein 4 and ectopic fat deposition. Fertil Steril 2012; 97:1009-1015.
40. Hudson PL, Dougas I, Donahoe PK, et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990; 70:16-22.
41. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter-and intracycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010; 25:221-227.
42. Li HW, Anderson RA, Yeung WS, et al. Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea. Fertil Steril 2011; 96:774-779.
43. Rosenfield RL, Wroblewski K, Padmanabhan V, et al. Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012; 98:242-249.
44. Wang JG, Nakhuda GS, Guarnaccia MM, et al. Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196:77e71-77e75.
45. GrossmanMP, Nakajima ST, Fallat ME, Siow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 2008; 89:1364-1370.
46. Skalba P, Cygal A, Madej P, et al. Is the plasma anti-Mullerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2011; 158:254-259.
47. Pigny P, Merlen E, Robert Y, et al. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88:5957-5962.
48. Veiga-Lopez A, Ye W, Padmanabhan V. Developmental programming: prenatal testosterone excess disrupts anti-Mullerian hormone expression in preantral and antral follicles. Fertil Steril 2012; 97:748-756.
49. Crisosto N, Echiburu B, Maliqueo M, et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. Fertil Steril 2012; 97:218-224.
50. Lenarcik A, Bidzinska-Speichert B, Tworowska-Bardzinska U, Krepula K. Hormonal abnormalities in first-degree relatives of women with polycystic ovary syndrome (PCOS). Endokrynol Pol 2011; 62:129-133.
51. Legro RS, Bentley-Lewis R, Driscoll D, et al. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002; 87:2128-2133.
52. Crisosto N, Codner E, Maliqueo M, et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:2739-2743.
53. Sir-Petermann T, Ladron de Guevara A, Codner E, et al. Relationship between anti-Mullerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci 2012; 19:383-390.
54. Sir-Petermann T, Maliqueo M, Codner E, et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:4637-4642.
55. Ortega HH, Rey F, Velazquez MM, Padmanabhan V. Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep. Biol Reprod 2010; 82:1065-1075.
56. Abbott DH, Tarantal AF, Dumesic DA. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009; 71:776-784.
57. Xu N, Kwon S, Abbott DH, et al. Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One 2011; 6:e27286.
58. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43:55-59.
59. Zhao H, Xu X, Xing X, et al. Family-based analysis of susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Hum Reprod 2012; 27:294-298.
60. Lerchbaum E, Trummer O, Giuliani A, et al. Susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21, and 9q33.3 in a cohort of Caucasian women. Horm Metab Res 2011; 43:743-747.
61. Ewens KG, Jones MR, Ankener W, et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One 2011; 6:e16390.
62. Wehr E, Schweighofer N, Moller R, et al. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010; 59:575-580.
63. Tan S, Scherag A, Janssen OE, et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 2010; 11:12.
64. Goodarzi MO, Louwers YV, Taylor KD, et al. Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril 2011; 95:1736-1741; e1731-e1711.
65. Kim JJ, Choi YM, Cho YM, et al. Polycystic ovary syndrome is not associated with polymorphisms of the TCF7L2, CDKAL1, HHEX, KCNJ11, FTO and SLC30A8 genes. Clin Endocrinol 2012; 77:439-445.
66. O'Brien RF, Emans SJ. Polycystic ovary syndrome in adolescents. J Pediatr Adolesc Gynecol 2008; 21:119-128.
67. Vuguin PM. Interventional studies for polycystic ovarian syndrome in children and adolescents. Pediatr health 2010; 4:59-73.
68. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774-800.
69. Rossi B, Sukalich S, Droz J, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:4780-4786.
70. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48-53.
71. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91:492-497.
72. Vrbikova J, Zamrazilova H, Sedlackova B, Snajderova M. Metabolic syndrome in adolescents with polycystic ovary syndrome. Gynecol Endocrinol 2011; 27:820-822.
73. Hart R, Doherty DA, Mori T, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 2011; 95:2347-2353; 2353.e2341.
74. Nandalike K, Strauss T, Agarwal C, et al. Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. J Pediatr 2011; 159:591-596.
75. Shroff R, Kerchner A, Maifeld M, et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92:4609-4614.
76. Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 2005; 5:107-111.
77. Harris-Glocker M, Davidson K, Kochman L, et al. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril 2010; 93:1016-1019.
78. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol 2011; 117:145-152.
79. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics 2012; 129:1035-1041.
80. Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93:4299-4306.
81. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011; 24:161-165.
82. Lass N, Kleber M, Winkel K, et al. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011; 96:3533-3540.
83. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci 2000; 900:245-252.
84. Cibula D, Hill M, Fanta M, et al. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod 2001; 16:940-944.
85. Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol 2008; 68:800-805.
86. Allen HF, Mazzoni C, Heptulla RA, et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinolo Metab 2005; 18:761-768.
87. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160:241-246.
88. Ehrmann DA. Insulin resistance and polycystic ovary syndrome. Curr Diab Rep 2002; 2:71-76.
89. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in nonobese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17:1729-1737.
90. Mastorakos G, Koliopoulos C, Deligeoroglou E, et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006; 85:420-427.